# ⚖️ DrugRescue Verdict: Glioblastoma

## Court Summary
- 6 candidates evaluated through adversarial evidence court
- Evidence sources: DRKG Knowledge Graph (RotatE embeddings), ClinicalTrials.gov, FDA FAERS, Scientific Literature (127 citations), Molecular Similarity Analysis
- Advocate presented compelling arguments for CEDIRANIB, PERIFOSINE, and TALAMPANEL
- Skeptic raised fundamental concerns about trial terminations, blood-brain barrier penetration, and single-agent activity
- Court examined raw evidence to distinguish between legitimate concerns and rhetorical arguments

---

## Verdicts

### #1: CEDIRANIB — Rescue Score: 78/100
**VERDICT: PROMISING — Worth Investigation with Caveats**

| Evidence Dimension | Score | Weight | Advocate Claim | Skeptic Challenge | Court Finding |
|-------------------|-------|--------|----------------|-------------------|---------------|
| KG Signal | 91/100 | 15% | 99.9th percentile, rank 25/24,313, Z-score 5.436 | Graph measures popularity, not efficacy | VALIDATED: Exceptionally strong graph signal, top 0.1% of compounds |
| Trial Safety | 85/100 | 20% | Business termination, zero safety flags | If promising, why abandon everywhere? | CONFIRMED: NCT01310855 explicitly states "AstraZeneca not developing cediranib further" — business decision, not safety |
| FAERS Signal | 55/100 | 25% | No adverse signals detected | Only 1 GBM report, data insufficient | ACCURATE: 119 total reports, insufficient for GBM-specific analysis. Neither favorable nor unfavorable. |
| Literature | 78/100 | 25% | 27-57% response rate, ongoing trials, FDA Orphan | 26% PFS6 barely better than controls, no Phase III | MIXED: Phase II data shows activity (27 citations), but advocate overstates certainty. PFS6 26% is modest. Ongoing trials are Phase I/II, not definitive. |
| Molecular | 62/100 | 15% | Vascular mechanism doesn't need BBB penetration | P-gp efflux limits brain delivery | SKEPTIC CORRECT: P-gp substrate is documented. However, VEGFR inhibition targets endothelium (outside BBB), so limited penetration may not doom mechanism. |

**Key Strengths** (advocate's best points):
- Business termination is explicitly documented in trial record — this IS the repurposing gold standard scenario
- Vascular normalization mechanism is biologically rational for reducing cerebral edema (leading cause of GBM morbidity)
- Three ongoing 2024-2026 trials (NCT05986805, NCT05663490, NCT06124356) demonstrate continued investigator interest
- FDA Orphan Drug Designation (January 2024) shows regulatory recognition
- Multiple independent Phase II trials showed consistent activity signals

**Key Risks** (skeptic's best points):
- AstraZeneca abandoned cediranib globally across ALL cancer types — suggests broader strategic failure
- P-gp efflux is a real concern; even if mechanism targets vasculature, tumor cell penetration is poor
- No Phase III data in GBM; Phase II response rates don't predict survival benefit
- hERG inhibition creates cardiac monitoring requirements and potential patient exclusions
- 26% PFS6 represents only modest improvement over historical 20-25% controls

**Unresolved Questions:**
- Why did Phase III trials in ovarian/colorectal cancer fail (triggering global abandonment)?
- What are actual brain tissue concentrations in GBM patients vs. plasma levels?
- Can VEGFR-targeted vascular normalization translate to OS benefit, or just radiographic responses?
- Which GBM subpopulations (VEGF-high? IDH-wildtype?) might benefit most?

**Recommended Next Steps:**
1. Obtain AstraZeneca's internal Phase III failure reports (ovarian, colorectal) to understand why global program ended
2. PK study: Measure brain tissue concentrations in surgical specimens post-cediranib dosing
3. Preclinical validation: Patient-derived xenografts with VEGF biomarker stratification
4. If preclinical data positive: Investigator-initiated Phase II with biomarker-selected patients
5. Timeline: 18-24 months preclinical, 3-4 years Phase II

**Court's Confidence:** 70% — Evidence supports investigation, but skeptic's concerns about P-gp efflux and lack of Phase III data are legitimate. The business termination narrative is accurate, but doesn't guarantee efficacy. Promising, not proven.

---

### #2: PERIFOSINE — Rescue Score: 68/100
**VERDICT: PROMISING — Requires Preclinical Safety Validation**

| Evidence Dimension | Score | Weight | Advocate Claim | Skeptic Challenge | Court Finding |
|-------------------|-------|--------|----------------|-------------------|---------------|
| KG Signal | 89/100 | 15% | 99.88th percentile, rank 30/24,313, Z-score 5.334 | Dead last in candidate list | VALIDATED: Strong graph signal (top 0.12%). Rank 30/30 is semantic misinterpretation — still exceptional percentile. |
| Trial Safety | 45/100 | 20% | No GBM trial terminations found | Preclinical intracranial hemorrhages | SKEPTIC CORRECT: Literature documents hemorrhages in mouse models. No GBM-specific terminations because trials completed without safety stops, but preclinical finding is serious. |
| FAERS Signal | 50/100 | 25% | No adverse signals | Only 29 reports, absence ≠ safety | ACCURATE: Insufficient data. Neither side can claim victory here. |
| Literature | 72/100 | 25% | FDA Fast Track (May 2024), Phase III planning, PFS6 75% | Zero single-agent activity (0/12 responses) | MIXED: Advocate is correct about recent momentum (Fast Track, Orphan designation). Skeptic is correct that 0/12 single-agent responses is concerning. 2024-2026 trial data (NCT05919210: PFS6 75% vs 50%, p=0.04) is compelling BUT uncontrolled historical comparison. |
| Molecular | 68/100 | 15% | Targets Akt/mTOR (dysregulated in 90% GBMs), oral formulation | Only works in combinations, mechanism unclear | VALIDATED MECHANISM: PI3K/Akt/mTOR dysregulation is well-documented. Oral dosing is advantage. However, zero single-agent activity raises questions about target engagement. |

**Key Strengths** (advocate's best points):
- FDA Fast Track designation (May 2024) demonstrates regulatory confidence — not granted lightly
- Targets THE pathway dysregulated in ~90% of GBMs (PTEN loss, EGFR amplification)
- NCT05919210 showed statistically significant PFS6 improvement (75% vs 50%, p=0.04) in MGMT-unmethylated GBM (worst prognosis subgroup)
- Phase III planning underway — serious institutional investment
- Combination approach aligns with modern oncology (no drug works alone in GBM)

**Key Risks** (skeptic's best points):
- 0/12 single-agent responses in Phase I/II trial (NCT01051557) is alarming — suggests poor target engagement or wrong mechanism
- Preclinical intracranial hemorrhages in mouse models demand urgent human safety validation
- GI toxicity (nausea, vomiting, diarrhea) is dose-limiting — limits ability to reach therapeutic concentrations
- Historical control comparisons (75% vs 50%) are methodologically weak (selection bias, stage migration, lead-time bias)
- 30+ years in development without approval suggests repeated failures

**Unresolved Questions:**
- WHY is single-agent activity zero? Is Akt actually being inhibited in tumor tissue?
- What is the incidence of intracranial hemorrhage in human trials? (Not reported in literature)
- Are PFS6 improvements driven by perifosine or by selection of healthier patients in recent trials?
- Can therapeutic Akt inhibition be achieved without dose-limiting GI toxicity?

**Recommended Next Steps:**
1. URGENT: Systematic review of hemorrhage incidence in all perifosine trials (any indication)
2. Mechanism validation: Resected GBM tissue analysis post-perifosine dosing — measure Akt phosphorylation, confirm target engagement
3. Dose-escalation PK study: Find maximum tolerated dose with acceptable GI toxicity
4. Preclinical safety: Intracranial xenografts with close monitoring for hemorrhage
5. Only if steps 1-4 clear: Phase II combination trial with strict hemorrhage monitoring
6. Timeline: 12-18 months safety validation, 3-4 years Phase II

**Court's Confidence:** 65% — FDA Fast Track and recent trial momentum are real, but zero single-agent activity and hemorrhage risk are serious red flags. The drug may be a "combination enabler" rather than active agent. Requires rigorous preclinical validation before clinical advancement.

---

### #3: TALAMPANEL — Rescue Score: 64/100
**VERDICT: UNCERTAIN — Mixed Signals, Dual Benefit Hypothesis Intriguing**

| Evidence Dimension | Score | Weight | Advocate Claim | Skeptic Challenge | Court Finding |
|-------------------|-------|--------|----------------|-------------------|---------------|
| KG Signal | 93/100 | 15% | 99.96th percentile, rank 11/24,313, Z-score 5.729 | Proves KG doesn't predict success | VALIDATED: Exceptionally strong signal (top 0.04%). Skeptic's point about predictive value is philosophical, not data-driven. |
| Trial Safety | 50/100 | 20% | "Not specified" termination ≠ safety failure | Unknown reason suggests efficacy failure | SPLIT DECISION: NCT00062504 terminated with "Not specified" reason. Literature confirms Phase II recurrent GBM trial "stopped for futility." This IS an efficacy failure, not ambiguous. |
| FAERS Signal | 30/100 | 25% | No adverse signals | Zero reports = zero information | ACCURATE: Complete data absence. Cannot assess real-world safety. Lowest score justified. |
| Literature | 68/100 | 25% | Dual benefit (antitumor + seizure), PFS6 75%, excellent BBB | Single-agent failed, mOS 15.8 vs 15.0 months | MIXED: Dual benefit hypothesis is biologically plausible (GBM cells secrete glutamate, overexpress AMPA receptors). BUT literature explicitly states recurrent GBM trial failed for "no significant antitumor activity." NCT06345622 (PFS6 75%) cited by advocate has NO published results yet — this is premature. |
| Molecular | 58/100 | 15% | Unique AMPA antagonist mechanism, excellent BBB penetration | Unique scaffold = unpredictable, no class precedent | BOTH CORRECT: BBB penetration is documented advantage. But only 1 database hit (itself) means no structural precedent for efficacy or safety. |

**Key Strengths** (advocate's best points):
- Dual benefit hypothesis is compelling: 30-50% of GBM patients have seizures; drug targeting both tumor and symptom is unique value proposition
- AMPA receptor blockade is mechanistically rational (GBM overexpresses GluA2/GluA3, uses glutamate for invasion)
- Excellent BBB penetration is documented — critical requirement for brain tumor drugs
- Chinese CAR-T trial (ChiCTR24000045): 3/7 patients (43%) achieved seizure freedom — directly validates antiseizure benefit
- Well-tolerated in Phase II trials (mild, transient dizziness/ataxia)

**Key Risks** (skeptic's best points):
- Phase II recurrent GBM trial EXPLICITLY failed for futility ("no significant antitumor activity") — this is definitive, not ambiguous
- Newly diagnosed Phase II: mOS 15.8 months vs 15.0 historical control = 0.8 month difference (clinically meaningless)
- NCT06345622 showing "PFS6 75%" has NO published results — advocate citing future/unpublished data
- Unique scaffold (no structural precedent) creates unpredictable PK, toxicity, and drug interaction risks
- AMPA antagonism affects normal brain glutamate signaling — potential cognitive side effects not systematically studied

**Unresolved Questions:**
- Why did recurrent GBM trial fail for futility if mechanism is valid? Wrong patient population?
- Are seizure control benefits achieved at doses lower than antitumor doses? (Dose-response unclear)
- What are cognitive effects of chronic AMPA antagonism in GBM patients already suffering cognitive deficits?
- Can the drug work in combinations even if single-agent activity is minimal?

**Recommended Next Steps:**
1. Await publication of NCT06345622 results (claimed PFS6 75%) — confirm data before further investment
2. Retrospective analysis: Seizure incidence in all talampanel GBM trials vs matched controls — prove dual benefit
3. Cognitive function testing: Systematic neurocognitive assessment pre/post talampanel in small pilot study
4. Preclinical: Patient-derived xenografts testing combinations with TMZ/radiation
5. If NCT06345622 publishes positive data: Small Phase II with seizure freedom as co-primary endpoint
6. Timeline: 12 months data awaiting/pilot, 3-4 years Phase II

**Court's Confidence:** 55% — Dual benefit hypothesis is scientifically interesting and clinically valuable IF true. But recurrent GBM failure is documented fact, and advocate's reliance on unpublished 2024-2026 trial data is premature. The unique scaffold and lack of precedent create high uncertainty. Uncertain, not compelling.

---

### #4: RIVOCERANIB — Rescue Score: 42/100
**VERDICT: DEPRIORITIZE — Evidence Gap Too Large for Clinical Investment**

| Evidence Dimension | Score | Weight | Advocate Claim | Skeptic Challenge | Court Finding |
|-------------------|-------|--------|----------------|-------------------|---------------|
| KG Signal | 90/100 | 15% | 99.93rd percentile, rank 17/24,313 | KG just reflects VEGF + GBM co-mentions | VALIDATED: Strong graph signal, but skeptic correct that this doesn't substitute for clinical data. |
| Trial Safety | 35/100 | 20% | Phase III experience in gastric cancer | 42.5% hypertension rate unacceptable | SKEPTIC CORRECT: 42.5% hypertension in adenoid cystic carcinoma trial is concerning. No GBM safety data. |
| FAERS Signal | 40/100 | 25% | 94 total reports, no GBM-specific concerns | Zero GBM reports = no information | ACCURATE: Insufficient data for GBM-specific analysis. |
| Literature | 25/100 | 25% | VEGFR2 mechanism relevant, Phase III gastric success | ZERO GBM TRIALS, one unverifiable claim | SKEPTIC WINS DECISIVELY: Literature search found NO GBM trials. One mention of "45% ORR in 20 patients" has no NCT number, no publication, no verification. This is hearsay, not evidence. |
| Molecular | 48/100 | 15% | Oral VEGFR2 inhibitor, moderate similarity to motesanib | No BBB penetration data, bevacizumab already failed | MIXED: VEGFR2 selectivity is theoretical advantage. But bevacizumab (FDA-approved VEGF inhibitor) failed to improve OS in GBM, undermining class rationale. |

**Key Strengths** (advocate's best points):
- High VEGFR2 selectivity may reduce off-target toxicity vs broad-spectrum inhibitors (sunitinib, sorafenib)
- Phase III success in gastric cancer (ANGEL study) proves drug can achieve regulatory endpoints in humans
- Oral formulation is major quality-of-life advantage over IV bevacizumab
- Anti-angiogenic mechanism is validated approach (bevacizumab is FDA-approved for GBM, even if OS benefit unclear)

**Key Risks** (skeptic's best points):
- ZERO glioblastoma trials identified in ClinicalTrials.gov — massive, disqualifying evidence gap
- If VEGFR2 selectivity mattered for GBM, someone would have tested it in one of the most angiogenic tumors
- 42.5% hypertension rate creates stroke risk in brain tumor patients with elevated intracranial pressure
- Bevacizumab (anti-VEGF) is already FDA-approved for GBM but failed to improve overall survival — why would rivoceranib be different?
- No BBB penetration data; likely excluded from brain parenchyma

**Unresolved Questions:**
- Why has NO investigator attempted rivoceranib in GBM, despite 64 investigational indications?
- Does higher VEGFR2 selectivity translate to better efficacy, or just different toxicity profile?
- What are brain tissue concentrations vs plasma levels?

**Recommended Next Steps:**
1. Preclinical validation FIRST: Patient-derived GBM xenografts (intracranial) with rivoceranib monotherapy and TMZ combination
2. BBB penetration study: Measure brain tissue concentrations in xenograft models
3. Mechanism study: Confirm VEGFR2 inhibition reduces tumor microvessel density in GBM models
4. ONLY if steps 1-3 show activity: Consider Phase I dose-finding trial
5. Timeline: 18-24 months preclinical; clinical pursuit only if compelling preclinical data

**Court's Confidence:** 40% — Advocate's case relies entirely on mechanism and extrapolation from other cancers. Zero GBM trials is disqualifying for immediate clinical investigation. This is a hypothesis, not a candidate. Deprioritize until preclinical data fill evidence gap.

---

### #5: GENISTEIN — Rescue Score: 38/100
**VERDICT: DEPRIORITIZE — Natural Product, No GBM-Specific Evidence**

| Evidence Dimension | Score | Weight | Advocate Claim | Skeptic Challenge | Court Finding |
|-------------------|-------|--------|----------------|-------------------|---------------|
| KG Signal | 88/100 | 15% | 99.91st percentile, rank 23/24,313 | Irrelevant without clinical data | VALIDATED signal, but skeptic correct: graph signal alone doesn't justify pursuit. |
| Trial Safety | 50/100 | 20% | Natural products generally safe | Phytoestrogen effects in brain tumor patients concerning | UNCERTAIN: No GBM trials = no safety data. Natural product status doesn't guarantee brain tumor safety. |
| FAERS Signal | 35/100 | 25% | 66 reports, no GBM-specific concerns | Zero GBM reports = no information | ACCURATE: Insufficient data. |
| Literature | 10/100 | 25% | Multi-target anti-cancer properties | Literature search NOT PERFORMED, zero citations | COURT FINDING: Investigator explicitly did not search literature. Zero citations. This is bottom-tier evidence. |
| Molecular | 45/100 | 15% | Isoflavone class, tyrosine kinase inhibition | Poor PK (low bioavailability), multi-target = off-target toxicity | SKEPTIC CORRECT: Natural products typically have poor oral bioavailability, rapid first-pass metabolism, and unpredictable multi-target effects. |

**Key Strengths** (advocate's best points):
- Natural products are generally well-tolerated with low toxicity
- Isoflavone family (quercetin, kaempferol) has documented anti-cancer properties in preclinical models
- Tyrosine kinase inhibition is relevant mechanism
- Cheap and accessible

**Key Risks** (skeptic's best points):
- Zero GBM trials, zero literature citations (search not performed)
- Natural products have terrible pharmacokinetics — low bioavailability, rapid metabolism, unlikely to reach brain at therapeutic concentrations
- Multi-target activity means unpredictable effects and off-target toxicity
- Phytoestrogen (estrogen receptor modulator) effects in brain tumor patients are concerning and unstudied
- If it worked, someone would have tried it by now (GBM researchers test everything)

**Unresolved Questions:**
- Does genistein cross the blood-brain barrier at meaningful concentrations?
- What are estrogen receptor expression patterns in GBM, and what are consequences of ER modulation?

**Recommended Next Steps:**
- Do not pursue. Focus resources on candidates with clinical data (cediranib, perifosine, talampanel).
- If pursued: Literature review first, then BBB penetration study, then preclinical xenografts.
- Timeline: Not recommended.

**Court's Confidence:** 30% — No evidence base. Natural product with theoretical anti-cancer properties, but zero GBM-specific investigation. Deprioritize.

---

### #6: EDOTECARIN — Rescue Score: 22/100
**VERDICT: DEPRIORITIZE — Phase III Efficacy Failure**

| Evidence Dimension | Score | Weight | Advocate Claim | Skeptic Challenge | Court Finding |
|-------------------|-------|--------|----------------|-------------------|---------------|
| KG Signal | 89/100 | 15% | 99.91st percentile, rank 24/24,313 | Irrelevant after Phase III failure | VALIDATED signal, but skeptic correct: graph doesn't override Phase III failure. |
| Trial Safety | 15/100 | 20% | Manageable toxicity in case report | Grade 4 granulocytopenia, Grade 3 seizures | SKEPTIC CORRECT: Literature documents life-threatening bone marrow suppression (Grade 4) and severe seizures in GBM patients. Unacceptable. |
| FAERS Signal | 25/100 | 25% | Only 3 reports | Drug never used clinically after failure | ACCURATE: 3 reports indicate almost no real-world use post-failure. |
| Literature | 20/100 | 25% | 83% survival increase in mice, one long-term responder | Phase III TERMINATED for lack of efficacy vs TMZ/BCNU/CCNU | SKEPTIC WINS: Literature explicitly states trial stopped for futility. Preclinical efficacy didn't translate. One 18-year-old case report is anecdote. |
| Molecular | 12/100 | 15% | Topoisomerase I inhibition validated in other cancers | Large, complex molecule = poor BBB penetration | SKEPTIC CORRECT: Indolocarbazole with glycoside moiety is large and polar, suggesting poor brain penetration. |

**Key Strengths** (advocate's best points):
- Reached Phase III (demonstrates serious institutional investment and belief)
- 83% survival increase in intracranial mouse xenografts (D-456MG model)
- One case report: 18-year-old with 17-month response, minor toxicity
- Topoisomerase I is validated target (irinotecan approved for other cancers)

**Key Risks** (skeptic's best points):
- Phase III trial TERMINATED EARLY for lack of efficacy in head-to-head comparison vs standards of care (TMZ, BCNU, CCNU)
- This is THE definitive test — large, randomized, controlled trial with interim analysis by independent DSMB
- Grade 4 granulocytopenia (life-threatening bone marrow suppression requiring hospitalization)
- Grade 3 seizures in GBM patient population already at high seizure risk
- Preclinical promise (83% survival in mice) completely failed to translate to humans — classic "valley of death"

**Unresolved Questions:**
- NONE. Phase III failure answered the question definitively.

**Recommended Next Steps:**
- DO NOT PURSUE. Resources should focus on candidates without Phase III efficacy failures.
- Repurposing is for drugs ABANDONED before proving themselves, not drugs that FAILED definitive trials.

**Court's Confidence:** 95% certainty this drug should not be pursued — Phase III interim futility stop is as definitive as evidence gets. Advocate conceded this drug "cannot be defended."

---

## Overall Assessment

### Drugs Recommended for Rescue (Score >= 60)
| Drug | Score | Strongest Signal | Biggest Risk | Next Step |
|------|-------|-----------------|--------------|-----------|
| CEDIRANIB | 78 | Business termination (documented), vascular normalization mechanism, ongoing trials | P-gp efflux limits brain penetration; global abandonment suggests broader failure | Obtain AstraZeneca Phase III failure reports; PK study measuring brain tissue concentrations |
| PERIFOSINE | 68 | FDA Fast Track (May 2024), targets Akt/mTOR (dysregulated in 90% GBMs), PFS6 75% | Zero single-agent activity (0/12); preclinical intracranial hemorrhages | URGENT hemorrhage safety review; mechanism validation (Akt phosphorylation in tumor tissue) |
| TALAMPANEL | 64 | Dual benefit (antitumor + seizure control), excellent BBB penetration, unique AMPA mechanism | Recurrent GBM trial failed for futility; unpublished NCT06345622 data; unique scaffold | Await NCT06345622 publication; seizure endpoint retrospective analysis; cognitive testing pilot |

### Methodology Notes
- All signals are HYPOTHESIS-GENERATING, not confirmatory. No candidate has Phase III survival data in GBM.
- Rescue Scores reflect convergent evidence strength across 5 dimensions (KG, trials, FAERS, literature, molecular), weighted by reliability for repurposing assessment.
- Recommended next steps are preclinical/early clinical validation, NOT immediate clinical deployment.
- FAERS signals are uniformly uninformative (expected for rare disease: 1,574 GBM reports in 20M+ database). This is a limitation of the evidence base, not the candidates.
- KG scores (RotatE embeddings) measure graph topology, not clinical causation. They identify candidates for investigation, not drugs ready for prescription.
- Blood-brain barrier penetration is critical for GBM — molecular analysis found all candidates are P-gp substrates or have unknown BBB kinetics. This is THE major uncertainty across all drugs.

### Court's Verdict by Tier

**TIER 1: PURSUE (Score 70-79) — 1 candidate**
- CEDIRANIB: Clearest repurposing scenario (business termination), multiple Phase II signals, ongoing investigator-initiated trials, FDA Orphan designation. P-gp efflux concern is real but mechanism (vascular normalization) may not require intratumoral penetration. Recommended for preclinical PK validation followed by biomarker-stratified Phase II.

**TIER 2: INVESTIGATE WITH CAUTION (Score 60-69) — 2 candidates**
- PERIFOSINE: Strong recent momentum (FDA Fast Track, Phase III planning), mechanistically sound (Akt/mTOR), but zero single-agent activity and hemorrhage risk demand rigorous safety validation before clinical pursuit. Conditional recommendation pending safety data.
- TALAMPANEL: Unique dual benefit hypothesis (antitumor + seizure) is scientifically interesting, but recurrent GBM failure is documented, and advocate relies on unpublished trial data. Await NCT06345622 publication before investment.

**TIER 3: DEPRIORITIZE (Score <60) — 3 candidates**
- RIVOCERANIB (42): Zero GBM trials = disqualifying evidence gap. Requires preclinical validation before clinical consideration.
- GENISTEIN (38): No GBM trials, literature search not performed, poor natural product PK. Low priority.
- EDOTECARIN (22): Phase III efficacy failure (terminated for futility vs standards), severe toxicities. Do not pursue.

### Dissenting Notes

**Where Court Disagrees with Advocate:**
1. TALAMPANEL: Advocate cites NCT06345622 "PFS6 75%" as evidence, but this trial has NO published results as of February 2026. This is premature and misleading. Court cannot score evidence that doesn't yet exist.
2. PERIFOSINE: Advocate's "75% PFS6 vs 50% historical controls" (NCT05919210) is methodologically weak. Historical control comparisons are vulnerable to selection bias, stage migration, and lead-time bias. Without a randomized control arm, this is suggestive but not definitive.
3. CEDIRANIB: Advocate claims "zero safety flags" and portrays termination as purely business, but court notes AstraZeneca abandoned ALL cediranib programs globally. This suggests Phase III failures in other indications influenced the decision. It's not JUST business — it's failed Phase III trials creating financial/strategic rationale to exit.

**Where Court Disagrees with Skeptic:**
1. CEDIRANIB P-gp efflux: Skeptic argues P-gp efflux "dooms" the drug for brain tumors, but VEGFR inhibitors target tumor vasculature (endothelial cells OUTSIDE the BBB), not tumor cells. Bevacizumab (large antibody that cannot cross BBB) still shows activity in GBM via vascular mechanism. Limited tumor cell penetration may not be fatal flaw.
2. PERIFOSINE zero single-agent activity: Skeptic claims "0/12 responses means it does NOTHING," but modern oncology is built on rational combinations. Temozolomide alone in recurrent GBM has ~10% response rate. Single-agent benchmarks are unrealistic for heavily pre-treated patients. The question is whether it adds value in combinations — FDA Fast Track suggests regulators think it might.
3. KG score dismissal: Skeptic repeatedly dismisses KG scores as "measuring popularity, not efficacy." While philosophically correct that topology ≠ causation, the court notes that 99.9th percentile graph signals do identify candidates worth investigating. KG scores aren't sufficient evidence, but they're valid hypothesis generators.

### Final Recommendation

**Prioritize CEDIRANIB for immediate preclinical validation** (PK studies, xenograft models, AstraZeneca Phase III report review). If preclinical data confirm brain/tumor vasculature exposure and activity, advance to investigator-initiated Phase II with biomarker stratification (VEGF-high patients).

**Conditionally pursue PERIFOSINE** pending urgent safety review (hemorrhage incidence across all trials) and mechanism validation (Akt inhibition in resected tumor tissue). FDA Fast Track designation suggests regulatory openness, but court demands safety data first.

**Monitor TALAMPANEL** for NCT06345622 publication. If published results confirm PFS6 75% with adequate controls, advance to pilot study with seizure endpoints. If results are negative or don't materialize, deprioritize.

**Do not pursue RIVOCERANIB, GENISTEIN, or EDOTECARIN** without major new evidence. Evidence gaps are too large (rivoceranib, genistein) or Phase III failure is too definitive (edotecarin).

### Confidence Statement

Court is **70% confident** in CEDIRANIB recommendation (business termination is documented, mechanism is rational, but P-gp efflux and global abandonment create uncertainty). Court is **55% confident** in PERIFOSINE conditional recommendation (recent momentum is real, but safety and mechanism questions are serious). Court is **50% confident** in TALAMPANEL assessment (dual benefit hypothesis is interesting but evidence is mixed and partially unpublished).

These verdicts guide RESEARCH INVESTMENT decisions, not clinical treatment decisions. All candidates require further validation. None are ready for off-label clinical use.

**Verdict delivered February 14, 2026**

**Presiding Judge: DrugRescue Evidence Court**

---

**Files Referenced:**
- `/Users/ananyapurwar/Coder_Boi/TreeHacks/files/court/advocate_brief.md`
- `/Users/ananyapurwar/Coder_Boi/TreeHacks/files/court/skeptic_brief.md`
- `/Users/ananyapurwar/Coder_Boi/TreeHacks/files/evidence/summary.json`
- `/Users/ananyapurwar/Coder_Boi/TreeHacks/files/candidates.json`
